1636180-98-7

1636180-98-7 structure
1636180-98-7 structure
  • Name: tarloxotinib bromide
  • Chemical Name: tarloxotinib bromide
  • CAS Number: 1636180-98-7
  • Molecular Formula: C24H24Br2ClN9O3
  • Molecular Weight: 681.767
  • Catalog: Research Areas Cancer
  • Create Date: 2019-01-20 23:20:00
  • Modify Date: 2024-01-08 17:26:49
  • Tarloxotinib bromide is an irreversible EGFR/HER2 inhibitor.

Name tarloxotinib bromide
Synonyms 1H-Imidazole-5-methanaminium, N-[(2E)-4-[[4-[(3-bromo-4-chlorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxo-2-buten-1-yl]-N,N,1-trimethyl-4-nitro-, bromide (1:1)
tarloxotinib bromide
3Y31FJ8K50
(2E)-4-({4-[(3-Bromo-4-chlorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl}amino)-N,N-dimethyl-N-[(1-methyl-4-nitro-1H-imidazol-5-yl)methyl]-4-oxo-2-buten-1-aminium bromide
Description Tarloxotinib bromide is an irreversible EGFR/HER2 inhibitor.
Related Catalog
Target

EGFR/HER2

In Vitro To confirm the mechanism of action, Tarloxotinib bromide is shown to be metabolized efficiently under hypoxia using a panel of human NSCLC cell lines (rate of TKI release 0.4-2.1 nM/hr/106 cells), a process that is inhibited by oxygen (TKI release <0.002 nM/hr/106 cells). Cellular anti-proliferative and receptor phosphorylation assays demonstrate a 14-80 fold reduction of Tarloxotinib bromide activity relative to TKI. Using PC9 tumors, hyperbaric oxygen breathing suppresse release of TKI from Tarloxotinib bromide by >80% (538 vs 99 nM/kg; p<0.01) compared to air breathing controls. Collectively, these data further validate that Tarloxotinib bromide is a hypoxia-activated irreversible EGFR-TKI, and show that Tarloxotinib bromide has greater activity compared with erlotinib[2].
In Vivo A prototypic WT EGFR driven xenograft model (A431) is used to benchmark Tarloxotinib bromide activity against each EGFR-TKI by ‘retrotranslation’ of reported plasma exposure for each agent in human subjects back to the xenograft model. Only treatment with clinically relevant doses and schedules of Tarloxotinib bromide is associated with tumor regression and durable inhibition of WT EGFR tumor phosphorylation. Consistent with these findings, Tarloxotinib bromide treatment can also regress the WT EGFR NSCLC tumor models H125 and H1648, demonstrating Tarloxotinib bromide provides the necessary therapeutic index to inhibit WT EGFR in vivo[1].
References

[1]. Shevan Silva, Abstract A67: Preclinical efficacy of tarloxotinib bromide (TH-4000), a hypoxia-activated EGFR/HER2 inhibitor: rationale for clinical evaluation in EGFR mutant, T790M-negative NSCLC following progression on EGFR-TKI therapy. Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 5-9, 2015; Boston, MA.

[2]. Adam V. Patterson, Abstract 5358: The hypoxia-activated EGFR-TKI TH-4000 overcomes erlotinib-resistance in preclinical NSCLC models at plasma levels achieved in a Phase 1 clinical trial. AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA.

Molecular Formula C24H24Br2ClN9O3
Molecular Weight 681.767
Exact Mass 679.005737
Storage condition 2-8℃